ライフサイエンスコーパス: alcoholic fatty liver

1 as significantly higher in patients with non-alcoholic fatty liver.

2 rity of liver steatosis in subjects with non-alcoholic fatty liver.

3 ers of oxidative stress in subjects with non-alcoholic fatty liver.

4 tissue (WAT)-liver axis in a mouse model of alcoholic fatty liver.

5 een adipose fat loss and hepatic fat gain in alcoholic fatty liver.

6 the plasma leptin concentration and reversed alcoholic fatty liver.

7 to diseases like obesity, diabetes, and non-alcoholic fatty liver.

8 be a cryptic co-factor in some cases of non-alcoholic fatty liver.

9 n, fatty acid metabolism, and development of alcoholic fatty liver.

10 ethanol may contribute to the development of alcoholic fatty liver.

11 mediated fatty acid uptake may contribute to alcoholic fatty liver.

12 Willi syndrome - and reduced HFD-induced non-alcoholic fatty liver.

13 ion and faster fibrosis progression than non-alcoholic fatty liver.

14 idation, and triglyceride secretion leads to alcoholic fatty liver (AFL).

15 e in alcoholic liver disease, which includes alcoholic fatty liver, alcoholic hepatitis, and alcoholi

16 PGF2alpha were independent predictors of non-alcoholic fatty liver and a strong association of urinar

17 xidative stress markers in patients with non-alcoholic fatty liver and no study has been performed wi

18 ct of ethanol may promote the development of alcoholic fatty liver and other hepatic consequences of

19 isease, type 2 diabetes, atherosclerosis,non-alcoholic fatty liver, and cancer.

20 E-selectin was highly up-regulated in human alcoholic fatty livers, but not in alcoholic cirrhosis.

21 .4 x 10 -5 ), liver cancer ( p = 0.007), non-alcoholic fatty liver disease ( p = 7.7 x 10 -11 ), and

22 rhosis (14.5%), hepatitis C (13.4%), and non-alcoholic fatty liver disease (5.7%).

23 (NHANES) data to estimate the prevalence of alcoholic fatty liver disease (AFLD) overall and with st

24 In animal models for alcoholic fatty liver disease (AFLD), decontaminating th

25 Alcoholic fatty liver disease (ALD) and nonalcoholic fat

26 Participants with non-alcoholic fatty liver disease (defined as (1)H magnetic

27 5% CI: 2.51-33.50, p = 3.8 x 10 -7 ) and Non-alcoholic fatty liver disease (hazard ratio = 5.17, 95%

28 s and in a human cohort of subjects with non-alcoholic fatty liver disease (N = 146).

29 th adipose tissue insulin resistance and non-alcoholic fatty liver disease (n = 210, Germany).

30 Non-alcoholic and alcoholic fatty liver disease (NAFLD and AFLD, respectiv

31 models (n = 3-5) and in human samples of non-alcoholic fatty liver disease (NAFLD) (n = 72-135).

32 tudy, adult patients with definite NASH, non-alcoholic fatty liver disease (NAFLD) activity score of

33 Non-alcoholic fatty liver disease (NAFLD) affects 1 in 3 Ame

34 Non-alcoholic fatty liver disease (NAFLD) affects 20-30% of

35 Non-alcoholic fatty liver disease (NAFLD) affects 25% of the

36 Non-alcoholic fatty liver disease (NAFLD) affects a large pr

37 Non-alcoholic fatty liver disease (NAFLD) affects about 24%

38 Non-alcoholic fatty liver disease (NAFLD) affects nearly one

39 Non-alcoholic fatty liver disease (NAFLD) affects over 30% o

40 The prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among elderly have

41 d altered energy metabolism is common in non-alcoholic fatty liver disease (NAFLD) and appears to als

42 Non-alcoholic fatty liver disease (NAFLD) and cardiovascular

43 Sonic Hedgehog (SHH) is associated with Non-alcoholic fatty liver disease (NAFLD) and development of

44 carbohydrates, fat and calories leads to non-alcoholic fatty liver disease (NAFLD) and hepatic insuli

45 gut microbiota in choline deficiency in non-alcoholic fatty liver disease (NAFLD) and insulin resist

46 hermogenesis, promoting greater obesity, non-alcoholic fatty liver disease (NAFLD) and insulin resist

47 Non-alcoholic fatty liver disease (NAFLD) and its more sever

48 milar to those observed in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic

49 Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic

50 amine the associations of adiposity with non-alcoholic fatty liver disease (NAFLD) and other chronic

51 syndrome, obesity, type II diabetes and non-alcoholic fatty liver disease (NAFLD) are increasing and

52 ease especially in diabetes mellitus and non-alcoholic fatty liver disease (NAFLD) but studies examin

53 ne fetuin-A may impair renal function in non alcoholic fatty liver disease (NAFLD) by altering inflam

54 Increasing incidence of non-alcoholic fatty liver disease (NAFLD) calls for improved

55 erum XPO4 pattern in a broad spectrum of non-alcoholic fatty liver disease (NAFLD) cases.

56 Non-alcoholic fatty liver disease (NAFLD) characterizes and

57 ng greater weight loss and reductions in non-alcoholic fatty liver disease (NAFLD) compared to calori

58 Non-alcoholic fatty liver disease (NAFLD) comprises a range

59 Non-alcoholic fatty liver disease (NAFLD) constitutes a meta

60 and more effective hepatitis C therapy, non-alcoholic fatty liver disease (NAFLD) could soon emerge

61 The approach was developed on a non-alcoholic fatty liver disease (NAFLD) data set.

62 non-invasive fibrosis scoring system for non-alcoholic fatty liver disease (NAFLD) derived from routi

63 Although the progression of non-alcoholic fatty liver disease (NAFLD) from steatosis to

64 Non-alcoholic fatty liver disease (NAFLD) has a global preva

65 Non-alcoholic fatty liver disease (NAFLD) has become the mos

66 Non-alcoholic fatty liver disease (NAFLD) has become the mos

67 Non-alcoholic fatty liver disease (NAFLD) has been recently

68 Non-alcoholic fatty liver disease (NAFLD) has emerged as the

69 iver function in bariatric patients with non-alcoholic fatty liver disease (NAFLD) in a randomized cl

70 ent studies have raised the concept that non-alcoholic fatty liver disease (NAFLD) in adults is disti

71 lipogenesis are also central features of non-alcoholic fatty liver disease (NAFLD) in both rodents an

72 its pathologies in rodents that resemble non-alcoholic fatty liver disease (NAFLD) in humans through

73 Non-alcoholic fatty liver disease (NAFLD) in lean patients d

74 Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T

75 Mitochondrial adaptation during non-alcoholic fatty liver disease (NAFLD) include remodeling

76 The incidence of non-alcoholic fatty liver disease (NAFLD) increases with age

77 Almost all effective treatments for non-alcoholic fatty liver disease (NAFLD) involve reduction

78 Non-alcoholic fatty liver disease (NAFLD) is a common chroni

79 Non-alcoholic fatty liver disease (NAFLD) is a common metabo

80 Non-alcoholic fatty liver disease (NAFLD) is a complex chron

81 Non-alcoholic fatty liver disease (NAFLD) is a frequent cond

82 Non-alcoholic fatty liver disease (NAFLD) is a leading cause

83 Non-alcoholic fatty liver disease (NAFLD) is a major risk fa

84 Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive l

85 Non-alcoholic fatty liver disease (NAFLD) is a substantial c

86 Non-alcoholic fatty liver disease (NAFLD) is an emerging dis

87 Non-alcoholic fatty liver disease (NAFLD) is an increasingly

88 people living with HIV (PLWH), of which non-alcoholic fatty liver disease (NAFLD) is an increasingly

89 Non-alcoholic fatty liver disease (NAFLD) is an obesity- and

90 Non-alcoholic fatty liver disease (NAFLD) is becoming the le

91 Non-alcoholic fatty liver disease (NAFLD) is defined as a sp

92 he gut microbiome in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) is emerging.

93 Non-alcoholic fatty liver disease (NAFLD) is highly prevalen

94 The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing rapi

95 The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worl

96 the role of stress in the development of non-alcoholic fatty liver disease (NAFLD) is largely unexplo

97 Non-alcoholic fatty liver disease (NAFLD) is often associate

98 Non-alcoholic fatty liver disease (NAFLD) is one of the most

99 Non-alcoholic fatty liver disease (NAFLD) is one of the most

100 Non-alcoholic fatty liver disease (NAFLD) is one of the most

101 The prevailing theory in non-alcoholic fatty liver disease (NAFLD) is the "two-hit" h

102 Non-alcoholic fatty liver disease (NAFLD) is the hepatic man

103 Non-alcoholic fatty liver disease (NAFLD) is the most common

104 Non-alcoholic fatty liver disease (NAFLD) is the most common

105 Non-alcoholic fatty liver disease (NAFLD) is the most preval

106 However, its impact on non-alcoholic fatty liver disease (NAFLD) is unknown.

107 common causes of liver inflammation like non-alcoholic fatty liver disease (NAFLD) may increase the r

108 ed cellular lipid storage on obesity and non-alcoholic fatty liver disease (NAFLD) pathophysiology in

109 In non-alcoholic fatty liver disease (NAFLD) patients and obese

110 th sustained virological response and 93 non-alcoholic fatty liver disease (NAFLD) patients were incl

111 ted genes in the gastric tissue of obese non-alcoholic fatty liver disease (NAFLD) patients.

112 ith advanced liver fibrosis secondary to non-alcoholic fatty liver disease (NAFLD) remains challengin

113 Non-alcoholic fatty liver disease (NAFLD) represents a spect

114 The process initiates with non-alcoholic fatty liver disease (NAFLD) that progresses to

115 Increasing evidence connects non-alcoholic fatty liver disease (NAFLD) to CKD.

116 FXR and CAR in disease progression from non-alcoholic fatty liver disease (NAFLD) to HCC.

117 epatitis (NASH) is a progressive form of Non-alcoholic fatty liver disease (NAFLD), a chronic liver d

118 There is no licensed treatment for non-alcoholic fatty liver disease (NAFLD), a condition that

119 6), overweight children with and without non-alcoholic fatty liver disease (NAFLD), and children with

120 ly affected by the metabolic syndrome as non-alcoholic fatty liver disease (NAFLD), but may contribut

121 ome (PCOS) is frequently associated with non-alcoholic fatty liver disease (NAFLD), but the mechanism

122 esis are critical for the progression of non-alcoholic fatty liver disease (NAFLD), but the underlyin

123 tophagy is associated with steatosis and non-alcoholic fatty liver disease (NAFLD), however the mecha

124 In non-alcoholic fatty liver disease (NAFLD), lipid build-up an

125 is decreased in human liver samples with non-alcoholic fatty liver disease (NAFLD), non-alcoholic ste

126 4) that associate with increased risk of non-alcoholic fatty liver disease (NAFLD), non-alcoholic ste

127 od spot testing-is often misdiagnosed as non-alcoholic fatty liver disease (NAFLD), non-alcoholic ste

128 h chronic hepatitis B (CHB) and 488 with non-alcoholic fatty liver disease (NAFLD), those with rs1297

129 ic metabolic diseases including obesity, non-alcoholic fatty liver disease (NAFLD), type 2 diabetes a

130 ng recessive male-specific lethality and non-alcoholic fatty liver disease (NAFLD), which coincides w

131 Non-alcoholic fatty liver disease (NAFLD), which includes st

132 Obesity triggers the development of non-alcoholic fatty liver disease (NAFLD), which involves al

133 isms differ in drug induced (DIS) and/or non-alcoholic fatty liver disease (NAFLD).

134 creased oxidative damage are features of non-alcoholic fatty liver disease (NAFLD).

135 as a potential plasma marker to diagnose non-alcoholic fatty liver disease (NAFLD).

136 BR) is beneficial for obesity-associated non-alcoholic fatty liver disease (NAFLD).

137 icacy of sevelamer in treating mice with non-alcoholic fatty liver disease (NAFLD).

138 Visceral obesity is often accompanied by non-alcoholic fatty liver disease (NAFLD).

139 n (HP)-diet and/or beta-cryptoxanthin in non-alcoholic fatty liver disease (NAFLD).

140 at parallel stages in the development of non-alcoholic fatty liver disease (NAFLD).

141 r related complications in patients with non-alcoholic fatty liver disease (NAFLD).

142 ation, a characteristic of patients with non-alcoholic fatty liver disease (NAFLD).

143 might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD).

144 ated with the development of obesity and non-alcoholic fatty liver disease (NAFLD).

145 icoids contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD).

146 processing, are significantly altered in non-alcoholic fatty liver disease (NAFLD).

147 uman pathologies, including fibrosis and non-alcoholic fatty liver disease (NAFLD).

148 epatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).

149 particularly relevant in the context of non-alcoholic fatty liver disease (NAFLD).

150 the circadian clock desynchrony-mediated Non-alcoholic fatty liver disease (NAFLD).

151 y of liver disease or varying degrees of non-alcoholic fatty liver disease (NAFLD).

152 rs protection against the development of non-alcoholic fatty liver disease (NAFLD).

153 erse health outcomes in humans including non-alcoholic fatty liver disease (NAFLD).

154 c 12-hour clock and promotes spontaneous non-alcoholic fatty liver disease (NAFLD).

155 s, and hepatic features in patients with non-alcoholic fatty liver disease (NAFLD).

156 ic control in pre-diabetic patients with non-alcoholic fatty liver disease (NAFLD).

157 d with metabolic abnormalities including non-alcoholic fatty liver disease (NAFLD).

158 creased oxidative damage are features of non-alcoholic fatty liver disease (NAFLD).

159 ein F (APO-F), a potential biomarker for non-alcoholic fatty liver disease (NAFLD).

160 eatosis both in an inbred mouse model of non-alcoholic fatty liver disease (SJL/J) and in a humanized

161 liver histology defined as a decrease in non-alcoholic fatty liver disease activity score by at least

162 ) with biopsy-confirmed MASH (defined as non-alcoholic fatty liver disease activity score of 4 or hig

163 t), as well as elevated inflammation and non-alcoholic fatty liver disease activity scores, and hepat

164 In 2021, the estimated global cases of non-alcoholic fatty liver disease among adolescents and youn

165 ammation and fibrosis in mouse models of non-alcoholic fatty liver disease and advanced fibrosis, as

166 ly, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver

167 abetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease and autoimmune and neurode

168 both the metabolic syndrome accompanying non-alcoholic fatty liver disease and cellular apoptosis, we

169 Increases in non-alcoholic fatty liver disease and drug-induced hepatotox

170 Non-alcoholic fatty liver disease and early fibrosis were in

171 ss is an effective strategy for treating non-alcoholic fatty liver disease and improving insulin sens

172 Non-alcoholic fatty liver disease and its downstream sequela

173 a substantial overlap with biomarkers of non-alcoholic fatty liver disease and its progression to ste

174 Low aerobic capacity increases risk for non-alcoholic fatty liver disease and liver-related disease

175 ma lipoprotein metabolism, alcoholic and non-alcoholic fatty liver disease and myocardial infarction

176 o be of relevance for the development of non-alcoholic fatty liver disease and obesity.

177 to various metabolic diseases, including non-alcoholic fatty liver disease and type 2 diabetes.

178 could alleviate the related epidemics of non-alcoholic fatty liver disease and type 2 diabetes.

179 r treating inflammatory diseases such as non-alcoholic fatty liver disease and type 2 diabetes.

180 Ninety four eligible patients who have non-alcoholic fatty liver disease and who are insulin resist

181 lications such as insulin resistance and non-alcoholic fatty liver disease are reaching epidemic prop

182 fy predictors of fibrosis progression in non-alcoholic fatty liver disease as a case study.

183 UT2 may contribute to the development of non-alcoholic fatty liver disease by facilitating the uptake

184 gulation of the liver metabolism such as non-alcoholic fatty liver disease confer an increased risk o

185 patients had normal Fibrosis-4 Index and Non-alcoholic fatty liver disease fibrosis biomarker scores

186 and obesity are common in cirrhosis and non-alcoholic fatty liver disease has become an important ca

187 5 in vivo prior to or after establishing non-alcoholic fatty liver disease in mice.

188 y, and prevents metabolic stress-induced non-alcoholic fatty liver disease in mice.

189 fat accumulation and provides a model of non-alcoholic fatty liver disease in which to study the mech

190 Non-alcoholic fatty liver disease is a serious health proble

191 ion and fibrosis in humans and mice with non-alcoholic fatty liver disease is accompanied by accumula

192 Non-alcoholic fatty liver disease is associated with hepatoc

193 Non-alcoholic fatty liver disease is associated with multipl

194 Steatohepatitis due to non-alcoholic fatty liver disease is developing into a new a

195 Monitoring the progression of non-alcoholic fatty liver disease is hindered by a lack of s

196 The prevalence of non-alcoholic fatty liver disease is increasing worldwide an

197 d alcohol remain important risk factors, non-alcoholic fatty liver disease is rapidly becoming a domi

198 Non-alcoholic fatty liver disease is the most rapidly growin

199 The progressive non-alcoholic fatty liver disease observed in the LCR rats f

200 Remarkably, in non-alcoholic fatty liver disease patients, hepatic expressi

201 Non-alcoholic fatty liver disease ranges from steatosis to n

202 ucleotide variants in the progression of non-alcoholic fatty liver disease to non-alcoholic steatohep

203 buted to increasing rates of obesity and non-alcoholic fatty liver disease(2-4).

204 ients with histologically-defined NAFLD (non-alcoholic fatty liver disease) activity score (NAS) >= 4

205 iver disease (MASLD; previously known as non-alcoholic fatty liver disease) is the leading cause of c

206 (nonalcoholic fatty liver disease) and AFLD (alcoholic fatty liver disease).

207 holipase domain-containing protein 3 and non-alcoholic fatty liver disease, a previously reported add

208 s mellitus, insulin resistance (IR), and non-alcoholic fatty liver disease, although its role in obes

209 ty, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, and cancer.

210 a novel mechanistic link between T2D and non-alcoholic fatty liver disease, and demonstrate in vivo t

211 l syndrome, and metabolic (i.e. obesity, non-alcoholic fatty liver disease, and diabetes) and neurolo

212 progression of alcoholic liver disease, non-alcoholic fatty liver disease, and non-alcoholic steatoh

213 n both alcohol-related liver disease and non-alcoholic fatty liver disease, but rarely in hepatocellu

214 r rodents to high-calorie diets promotes non-alcoholic fatty liver disease, characterized by neutral

215 Non-alcoholic fatty liver disease, characterized in part by

216 of several metabolic diseases, including non-alcoholic fatty liver disease, diabetes mellitus, and ca

217 h risk factors of liver disease, such as non-alcoholic fatty liver disease, hazardous alcohol use, or

218 ce of different causes, such as obesity, non-alcoholic fatty liver disease, high alcohol consumption,

219 iet (HFD) consumption is associated with non-alcoholic fatty liver disease, increased apoptosis, and

220 liver injury mouse model recapitulating non-alcoholic fatty liver disease, injections of both HGF an

221 ver Disease (MAFLD), previously known as Non-Alcoholic Fatty Liver Disease, is a growing global healt

222 Given the increasing prevalence of non-alcoholic fatty liver disease, it is necessary to find a

223 d progression of liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepat

224 also able to reverse already established non-alcoholic fatty liver disease, resulting in significantl

225 Applied to non-alcoholic fatty liver disease, SCCAF-D unveils meaningfu

226 Non-alcoholic fatty liver disease, the most prevalent liver

227 In a diet-induced mouse model of non-alcoholic fatty liver disease, the sensor achieved overa

228 In a diet-induced mouse model of non-alcoholic fatty liver disease, the sensor achieved overa

229 about TM6SF2 and PNPLA3 polymorphisms in non-alcoholic fatty liver disease, their influence in the sp

230 tors contributing to the pathogenesis of non-alcoholic fatty liver disease, we examined liver steatos

231 e 2 diabetes mellitus has been linked to non-alcoholic fatty liver disease, which can progress to inf

232 These findings may also apply to non-alcoholic fatty liver disease, which shares similar path

233 cess alcohol intake, viral hepatitis and non-alcoholic fatty liver disease, with the clinical spectru

234 or progression of alcohol-associated and non-alcoholic fatty liver disease-the most common chronic li

235 lications of metabolic syndrome, such as non-alcoholic fatty liver disease.

236 n implicated in fatty liver formation in non-alcoholic fatty liver disease.

237 egulated de novo lipogenesis involved in non-alcoholic fatty liver disease.

238 vide unique targets for the treatment of non-alcoholic fatty liver disease.

239 therapeutic role of PHLPP2 activators in non-alcoholic fatty liver disease.

240 metabolic outcomes in participants with non-alcoholic fatty liver disease.

241 steatosis, a hallmark of human pediatric non-alcoholic fatty liver disease.

242 e liver fibrosis, mostly associated with non-alcoholic fatty liver disease.

243 at causes insulin-resistant diabetes and non-alcoholic fatty liver disease.

244 in-1 can be developed to treat patients with alcoholic fatty liver disease.

245 promising approach for the treatment of non-alcoholic fatty liver disease.

246 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.

247 , atherosclerotic vascular diseases, and non-alcoholic fatty liver disease.

248 s responsible for disease progression in non-alcoholic fatty liver disease.

249 latory protein and is highly up-regulated in alcoholic fatty liver disease.

250 ial for the prevention or treatment of human alcoholic fatty liver disease.

251 ycaemic, hyperinsulinaemic and developed non-alcoholic fatty liver disease.

252 tic link between adipokine dysregulation and alcoholic fatty liver disease.

253 plays a crucial role in the pathogenesis of alcoholic fatty liver disease.

254 reduction contributes to the pathogenesis of alcoholic fatty liver disease.

255 ential therapeutic target for treating human alcoholic fatty liver disease.

256 therapeutic target for diseases such as non-alcoholic fatty liver disease.

257 ential to treat both atherosclerosis and non-alcoholic fatty liver disease.

258 rongly associated with both nonalcoholic and alcoholic fatty liver disease.

259 sent a novel avenue for the treatment of non-alcoholic fatty liver disease.

260 robably increasing the susceptibility to non-alcoholic fatty liver disease.

261 concomitant protection from diet-induced non-alcoholic fatty liver disease.

262 hepatocyte lipoapoptosis are features of non-alcoholic fatty liver disease.

263 modulation of adiponectin-in treating human alcoholic fatty liver disease.

264 including type 1 diabetes, obesity, and non-alcoholic fatty liver disease.

265 ulin resistance and an increased risk of non-alcoholic fatty liver disease.

266 ciated with obesity, type 2 diabetes and non-alcoholic fatty liver disease.

267 trols, alcohol-related liver disease and non-alcoholic fatty liver disease.

268 yme that is upregulated in patients with non-alcoholic fatty liver disease.

269 tabolic syndrome, diabetes mellitus, and non-alcoholic fatty liver disease.

270 somatic mutation in alcohol-related and non-alcoholic fatty liver disease.

271 diseases, including type 2 diabetes and non-alcoholic fatty liver disease.

272 icial effects that have implications for non-alcoholic fatty liver disease.

273 resistance, type 2 diabetes mellitus and non-alcoholic fatty liver disease.

274 itigate the complications of obesity and non-alcoholic fatty liver disease.

275 ction in other hepatic diseases, such as non-alcoholic fatty liver disease.

276 res of the metabolic syndrome, including non-alcoholic fatty liver disease.

277 s (ROS) contribute to the development of non-alcoholic fatty liver disease.

278 lic diseases such as type 2 diabetes and non-alcoholic fatty liver disease.

279 atitis C and emergence of cirrhosis from non-alcoholic fatty liver disease.

280 tabolic conditions including obesity and non-alcoholic fatty liver disease.

281 atherosclerosis, increased obesity, and non-alcoholic fatty liver disease.

282 might be a novel therapeutic target for non-alcoholic fatty liver disease.

283 MKK2 function confers protection against non-alcoholic fatty liver disease.

284 adipocyte hypertrophy, and present with non-alcoholic fatty liver disease; 3) DKO mice demonstrate H

285 Non-alcoholic fatty-liver disease (NAFLD) is frequent in obe

286 Patients with non-alcoholic fatty liver had higher (p < 0.001) mean values

287 whether CYP2E1 plays a role in experimental alcoholic fatty liver in an oral ethanol-feeding model.

288 of saturated fat against the development of alcoholic fatty liver in mice is partially mediated thro

289 cate that CYP2E1 contributes to experimental alcoholic fatty liver in this model and suggest that CYP

290 Alcoholic fatty liver is the earliest and most common re

291 Non-alcoholic fatty liver is the most common liver disease w

292 r of transcription 3 (STAT3) and ameliorates alcoholic fatty liver, liver injury, and hepatic oxidati

293 Non-alcoholic fatty liver (NAFL) and related syndromes affec

294 vascular (CVD), chronic kidney (CKD) and non-alcoholic fatty liver (NAFLD) disease risk.

295 Leptin is a vital biomarker of non-alcoholic fatty liver (NAFLD), and its evaluation of the

296 mide probe to evaluate their inactivation in alcoholic fatty livers of rats.

297 on of their cysteine or tyrosine residues in alcoholic fatty livers of rats.

298 lipolysis pathway was altered in a model of alcoholic fatty liver, primary hepatocytes from rats fed

299 tosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis

300 onsumption contributes to the development of alcoholic fatty liver, which can be overcome by Wy14,643